Pharmalucence traces its roots to CIS-US, Inc. CIS-US was incorporated in 1985 to commercialize medical applications from isotopic technologies developed by its European parent company.
In mid-2007, Pharmalucence was created via the management buy-out of CIS-US by three long-term employees who shared the vision to become both an advanced contract manufacturing organization (CMO) and a leading manufacturer of radiopharmaceuticals.
Pharmalucence received approval of its first new product, the hepatobiliary imaging agent generic Mebrofenin, in 2008. In July 2009, Pharmalucence received approval for its generic Sestamibi, an agent used in millions of myocardial perfusion imaging studies annually.
In 2011 and 2012, Pharmalucence received FDA approval for two new indications for its Sulfur Colloid product. Upon receipt of these approvals, Sulfur Colloid is now indicated to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma when used with a hand-held gamma counter.
In 2012, we began our phased in move to our new manufacturing facility and company headquarters in Billerica MA.
On July 15, 2014, Pharmalucence was acquired by Sun Pharmaceuticals.
On April 25, 2016, Pharmalucence received FDA approval to begin manufacturing operations at its new Billerica MA facility.